NCT00779428View on ClinicalTrials.gov

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2013

Study Completion Date

July 31, 2013

Conditions
Advanced Malignancies
Interventions
DRUG

Tanespimycin

"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY